BSG guidance reframes colorectal polyp decisions when life expectancy is limited
Managing colorectal polyps in patients with a life expectancy under 10 years is rarely straightforward. The central problem is familiar to endoscopists and colorectal surgeons alike: a polyp may never progress to symptomatic cancer within the patient’s remaining lifespan, yet removal carries immediate procedural risk, and those harms rise as frailty, multimorbidity, and antithrombotic therapy accumulate. The new British Society of Gastroenterology and Association of Coloproctologists of Great Britain and Ireland guidance is designed to make that trade-off less opaque.
It does so by moving the conversation away from instinct and toward a structured estimate of competing risk. The document asks clinicians to weigh the probability of a polyp evolving into clinically meaningful malignancy against the likelihood of a polypectomy complication in an older or medically complex patient. In practice, that means the threshold for intervention is no longer driven only by lesion size or morphology. Prognosis, comorbidity burden, medication profile, and the consequences of a complication all become part of the same decision.
How the consensus group built the framework
The guidance development group brought together 28 members spanning gastroenterology, colorectal surgery, elderly care medicine, anaesthesia, epidemiology, nurse endoscopy, general practice, and patient representation. That mix matters because this is not purely an endoscopic question. It is also a survival question, a peri-procedural risk question, and a patient-preference question, particularly when the expected benefit of removing a lesion may not be realized within the patient’s lifetime.
To build the framework, the group collated estimates from literature searches on several linked domains: life expectancy stratified by age and comorbidity, dwell time for polyps of different sizes, cancer sojourn time, and complication rates after polypectomy in older or comorbid patients, including those taking antithrombotic medication. Those inputs were then used in a model comparing the lifetime risk of symptomatic malignancy with the risk of significant complications. The point is not that any one estimate settles the question. It is that the decision can now be approached with a more explicit accounting of competing hazards.
A modified Delphi process then brought the group to consensus. After three rounds of voting, 33 recommendations were issued across 10 domains, covering principles, diagnostic investigation, life expectancy, polyp and cancer natural history, polypectomy risks, management recommendations, follow-up, decision-making practicalities, training and education, and future research.
Life expectancy changes the meaning of a polyp
A polyp in a healthy 55-year-old and a polyp in a patient with markedly limited prognosis are not equivalent clinical findings. In the latter setting, the natural history of the lesion may be slower than the patient’s remaining lifespan, which makes surveillance or conservative management more defensible than automatic removal. The guidance directly addresses that tension by linking polyp biology to expected survival rather than treating every lesion as an immediate threat.
The rationale is pathophysiologically sound. Most colorectal neoplasia follows a prolonged sequence from adenoma to carcinoma, and many lesions remain indolent for years. If a patient is unlikely to live long enough to experience symptomatic malignant transformation, the rationale for exposing them to procedural bleeding, perforation, cardiopulmonary stress, or post-procedural decompensation weakens substantially. In frail patients, even a minor adverse event can trigger a cascade that changes independence, mobility, and disposition long after the procedure itself.
One sentence captures the practical consequence: a technically successful polypectomy may still be the wrong decision.
The 40 clinical scenarios give clinicians a working map
The guidance includes a table summarizing whether polypectomy or conservative management may be favored across 40 clinical scenarios. Those scenarios vary by life expectancy, polyp size, and antithrombotic use. This is where the document becomes operational rather than merely conceptual. Clinicians are given a way to compare situations that often arise in real clinics: a small lesion in a patient with substantial comorbidity, a larger lesion in someone with moderate survival, or a patient whose thrombosis prevention regimen raises the procedural stakes.
Antithrombotic therapy is especially important because bleeding risk is not abstract in this setting. For some patients, interruption of therapy carries thrombotic risk; for others, continuing therapy increases the danger of bleeding if resection is pursued. The guidance folds that tension into the overall decision rather than isolating it as a separate checkbox. This is the kind of nuance that matters in elderly care and endoscopy, where a single intervention can have downstream consequences far beyond the colon.
Shared decision-making becomes a clinical requirement, not an afterthought
The framework is intended to support more objective and informed discussions between clinician and patient, with an individualized plan emerging from that conversation. That emphasis is appropriate because the right answer is rarely the same for every patient who has a polyp. Some will value avoiding procedure-related harm above theoretical cancer prevention. Others will accept a short-term procedural risk in exchange for future oncologic certainty. The guidance does not replace judgment; it disciplines it.
The practical value lies in making those discussions more explicit. Rather than speaking in generalities about “risk” and “benefit,” clinicians can anchor the discussion in life expectancy, polyp size, expected progression, and the procedural context. That can help reduce both undertreatment, where a truly concerning lesion is ignored, and overtreatment, where a patient undergoes intervention without realistic chance of benefit.
What this guidance does not settle
The document provides a structured framework, but it does not erase the uncertainty inherent in predicting individual prognosis or in estimating the natural history of every lesion. Real-world decision-making will still depend on the accuracy of life expectancy estimates, the precision of endoscopic assessment, and the patient’s own goals of care. A small change in frailty, functional status, or antithrombotic exposure may shift the balance between removal and observation.
The guidance also points to a future research agenda spanning the same unresolved areas it tries to organize: better prognostic tools, sharper estimates of polyp progression, and more robust complication data in older and comorbid patients. For now, the most useful contribution is a disciplined way to ask whether removing a particular polyp is likely to help the patient who is sitting in front of the clinician, not just the theoretical patient described by guidelines.